Michael Kinch

American academic and writer

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles. (August 2024)

|

Michael Kinch

Born|

Michael Scott Kinch

(1966-12-10) 10 December 1966 (age 58)

Hamilton, Ohio, U.S.

Alma mater| Ohio State University
Duke University
Scientific career
Fields| Microbiology, Immunology
Institutions| Stony Brook University
Long Island University Washington University
Yale University
Purdue University

Michael Scott Kinch (born 1966) is an American academic and Chief Innovation Officer at Stony Brook University. Prior to this, he was Associate Vice Chancellor at Washington University in St. Louis where he helped lead innovation and entrepreneurship activities.

Kinch is known for his research and writing about the fields of cancer biology and infectious disease and the history of biomedicine and pharmaceutical industry innovation

## Career

[edit]

Kinch began an independent research career focused upon cancer biology at Purdue University in West Lafayette, Indiana in 1996.[1] Though obtaining tenure in 2000, Kinch left academia in late 2001 to start and lead a cancer biology department at MedImmune, Inc. in Gaithersburg, MD.[2] In 2006, Kinch led research and development at Functional Genetics, Inc., a biotechnology focused upon cancer and infectious diseases, also located in Gaithersburg.[3] In late 2010, Kinch returned to academia, joining Yale University founding and leading the Yale Center for Drug Discovery in West Haven, CT. At that time, he began aggregating information about the sources of innovation and entrepreneurship responsible for the introduction of new medicines, a subject that would later serve as the subject for a series of trade books. In 2016, Kinch moved to Washington University School of Medicine, where he founded two centers, the Center for Drug Discovery and the Center for Research Innovation in Biotechnology, and to help lead innovation and entrepreneurship activities.[4]

In 2024, Michael Scott Kinch was appointed Chief Innovation Officer at Stony Brook University.[5]

## Writings

[edit]

Kinch has authored more than two hundred peer-reviewed scientific papers or patents and published three trade books.[6]

His first book, A Prescription for Change, is a popular science book, debuting in 2016, which details the history of drug development throughout history, culminating in the proposition that the rising inefficiency in drug discovery threatens our ability to develop new medicines.[7]

A second book, Between Hope and Fear (2018), chronicles the development of vaccines, ranging from the discovery of the first vaccine, which is commonly misattributed to Edward Jenner to recent times. This book also details the rise of anti-vaccine movement, which has commonly accompanied high-profile vaccines.[8][9] Kirkus Reviews called it "a riveting chronicle of one of the greatest accomplishments in the history of medical science."[10] A review in The Wall Street Journal advised that the book "ought to be read by parents and policy makers alike, and its message heeded by all."[11]

His third book, The End of the Beginning, provides a history of immune-based treatments for cancer. This book reveals that the foundations for modern therapies were established more than a century ago and chronicles the political struggles and scientific discoveries that led to a new generation of life-saving therapies.[12]

A fourth book, The Price of Health: The Modern Pharmaceutical Industry and the Betrayal of a History of Care details the causes of increasing drug prices. The book reveals these outcomes result from a combination of an increasing complexity in both the science and business of drug development and reimbursement.

## Books

[edit]

Kinch has written the following books:

Title  | Publication Date  | Genre  | Notes

|
|
|

A Prescription for Change: The Looming Crisis in Drug Development | November, 2016  | Science  |
Between Hope and Fear: A History of Vaccines and Human Immunity | July, 2018  | Science  |
The End of the Beginning: Cancer, Immunity and the Future of a Cure | April, 2019  | Science  |
The Price of Health: The Modern Pharmaceutical Industry and the Betrayal of a History of Care | April, 2021  | Healthcare  | Co-authored with Lori A. Weiman

## References

[edit]

1. ^ "Kinch, Michael S | Purdue OTC". inventions.prf.org. Retrieved July 21, 2020.
2. ^ "Coming Soon". leighhealth.com. Retrieved July 21, 2020.
3. ^ "Functional Genetics, Inc. Announces Two Separate Awards from the United States Defense Threat Reduction Agency (DTRA) to Combat Viral Diseases". December 1, 2006.
4. ^ "Michael Kinch, Ph.D. – Department of Biochemistry and Molecular Biophysics". Retrieved May 5, 2025.
5. ^ "WWW.CRIB.LIU.EDU | Michael S. Kinch". www.crib.liu.edu. Retrieved May 5, 2025.
6. ^ "Michael Kinch Google Scholar". www.google.com. Retrieved July 21, 2020.
7. ^ "A Prescription for Change | Michael Kinch". University of North Carolina Press. Retrieved July 21, 2020.
8. ^ "Between Hope and Fear". pegasusbooks.com. Retrieved July 21, 2020.
9. ^ Marsh, Henry (September 3, 2018). "The Sniping Scientists Whose Work Saved Millions of Lives (Published 2018)". The New York Times. ISSN 0362-4331. Retrieved October 9, 2020.
10. ^ "Book review: Between Hope and Fear". Kirkus Reviews. July 3, 2018.
11. ^ Bynum, William F. (August 17, 2018). "'Between Hope and Fear' Review: Anxieties Immune to Reason". Wall Street Journal. ISSN 0099-9660. Retrieved October 9, 2020.
12. ^ "The End of the Beginning". pegasusbooks.com. Retrieved July 21, 2020.

Authority control databases

International|

* VIAF

National|

* United States
* Israel

Academics|

* ORCID
* Scopus
* Google Scholar

Other|

* IdRef
* Yale LUX